10-Q: Clarivate Reports Q2 2026 Results, Divests LS&H Business

Clarivate Plc announced its second quarter 2026 financial results, reporting a net loss and detailing the agreement to divest its Life Sciences & Healthcare business for $600 million.

Summary

• Clarivate Plc reported a net loss of $268.6 million for the three months ended June 30, 2026, compared to a net loss of $72.0 million in the same period of 2025. For the six months ended June 30, 2026, the net loss was $308.8 million, compared to $175.9 million in the prior year.
• Total revenues for the second quarter of 2026 were $587.3 million, a decrease of 5.5% from $621.4 million in the second quarter of 2025. For the six months ended June 30, 2026, revenues were $1,172.8 million, down 3.5% from $1,215.1 million in the prior year.
• The company recorded a significant goodwill impairment charge of $221.7 million related to its Life Sciences & Healthcare (LS&H) segment.
• Clarivate entered into a definitive agreement to sell its LS&H business for $600 million, expected to close by the end of 2026. This segment will be presented as a discontinued operation starting in Q3 2026.
• Adjusted EBITDA for the second quarter was $247.2 million, with an Adjusted EBITDA margin of 42.1%, consistent with the prior year's quarter.
• Free cash flow for the six months ended June 30, 2026, was $122.9 million, a decrease from $160.6 million in the same period of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to increased net losses, declining revenues, and a significant goodwill impairment, despite some positive operational metrics like stable renewal rates and ACV growth.

Positives

• The company maintained its Adjusted EBITDA margin at 42.1% for the second quarter of 2026, consistent with the prior year.
• Organic ACV grew 1.5% compared to June 30, 2025, driven by improved product pricing.
• Total ACV increased by 3.1% compared to June 30, 2025, due to improved product pricing and FX movements.
• The annual renewal rate remained stable at 91.9% as of June 30, 2026.
• The divestiture of the LS&H business is expected to strengthen the balance sheet through reduced debt.
• The company anticipates that cash flow from operations, cash on hand, and borrowing capacity will be adequate for the next 12 months and the foreseeable future.

Negatives

• The company reported a net loss of $268.6 million for Q2 2026, a significant increase from the $72.0 million loss in Q2 2025.
• Total revenues decreased by 5.5% in Q2 2026 compared to Q2 2025, and by 3.5% for the six-month period.
• A substantial goodwill impairment charge of $221.7 million was recognized for the LS&H segment.
• Free cash flow decreased by 23% to $122.9 million for the first six months of 2026 compared to the prior year.
• The company is facing ongoing legal proceedings, including securities class action complaints, with an uncertain outcome and potential financial impact.

Risks

• Dependence on third parties for data and services.
• Increased access to free or inexpensive information sources impacting competitive position.
• Ability to compete in a highly competitive industry and adapt to rapidly changing technology.
• Maintaining high annual renewal rates for subscription services.
• Potential adverse effects from reductions in customers' research budgets or government funding.
• Loss of or inability to attract and retain key personnel.
• Exposure to risks from international operations, including tax consequences and currency fluctuations.
• Cybersecurity risks, including data breaches and unauthorized access to computer systems.

Future Outlook

The company anticipates that the proceeds from the LS&H divestiture will strengthen its balance sheet through reduced debt. It believes that cash flow from operations, available cash, and borrowing capacity will be adequate to service debt, meet liquidity needs, and fund capital expenditures and other business plans for the next 12 months and the foreseeable future. Future capital requirements will depend on factors including the LS&H sale, acquisitions, and product development spending.

Management Comments

• The company aims to fuel the world's greatest breakthroughs by harnessing the power of human ingenuity.
• The divestiture of the LS&H business is expected to allow the company to increase its focus on its A&G and IP businesses.
• The company believes that cash flow from operations, available cash on hand, borrowing capacity, and access to capital markets will be adequate to service debt, meet liquidity needs, and fund capital expenditures and other business plans for both the next 12 months and the foreseeable future.

Industry Context

StockSavvy.ai notes that the divestiture of a segment, particularly one facing impairment, is a common strategy for companies to streamline operations and focus on core, higher-growth areas. The continued focus on subscription revenues and ACV growth aligns with industry trends favoring recurring revenue models.

Comparison to Industry Standards

• Clarivate's Adjusted EBITDA margin of 41.6% for the first six months of 2026 is strong compared to many software and data analytics companies, though specific industry benchmarks vary widely.
• The annual renewal rate of 91.9% is generally considered good for subscription-based businesses, indicating strong customer retention.
• The decline in transactional revenues, partly attributed to customer migration to subscription offerings, is a trend observed across various SaaS (Software as a Service) providers as they mature their offerings.

Legal Proceedings

• Three putative securities class action complaints were filed in the U.S. District Court for the Eastern District of New York against Clarivate and certain executives/directors, alleging weaknesses in internal controls and financial reporting. These have been consolidated and amended, with ongoing litigation and motions.
• A related class action was filed in Pennsylvania state court asserting claims under the Securities Act of 1933, based on similar allegations regarding offering documents for share issuances in June and September 2021. This case is also ongoing with preliminary objections pending.

Stakeholder Impact

• Shareholders: Potential dilution from ongoing legal proceedings, but also potential for improved financial health post-divestiture and debt reduction.
• Employees: Restructuring costs indicate potential workforce reductions or changes related to the Value Creation Plan and LS&H divestiture.
• Creditors: The divestiture and expected debt reduction could improve the company's credit profile.
• Customers: Continued focus on subscription models and stable renewal rates suggest ongoing service provision, though product group wind-downs might impact certain offerings.

Next Steps

• Complete the divestiture of the Life Sciences & Healthcare business by the end of calendar year 2026.
• Present the LS&H business as a discontinued operation starting in the third quarter of 2026.
• Continue to focus on the Academia & Government (A&G) and Intellectual Property (IP) businesses.
• Strengthen the balance sheet through reduced debt using proceeds from the LS&H sale.
• Continue to manage restructuring costs associated with the Value Creation Plan.

Key Dates

Recommendation

While the divestiture of a non-core or underperforming segment and focus on core businesses are positive strategic moves, the significant increase in net losses, revenue decline, and ongoing legal challenges present considerable headwinds. The company's ability to execute its strategy and improve profitability will be key. A 'hold' recommendation reflects a balanced view of the strategic shift against current financial performance and litigation risks.

Keywords

Clarivate, SEC Filing, 10-Q, Quarterly Report, Financial Results, Divestiture, Goodwill Impairment, Life Sciences & Healthcare